Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

Summary by The Daily News
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar 30, 2026-

1 Articles

The Daily NewsThe Daily News
Center

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar 30, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Daily News broke the news in on Monday, March 30, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Framingham icon

Framingham

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal